Scientists have identified potential biomarkers in the urine of pregnant women that could lead to a non-invasive testing for those with a serious and complex multisystem disorder called preeclampsia.
Preeclampsia occurs in the second half of pregnancy and is characterised by high blood pressure and proteinuria - a significant increase in the normal level of protein in the urine.
Women with the condition suffer headaches, swelling, fainting, and other unpleasant and often dangerous symptoms.
Ultimately, preeclampsia puts the health and life of an expectant mother and her baby at serious risk.
The symptoms of the condition are ambiguous, so doctors rarely diagnose "pure" preeclampsia. But with the new research, things could soon change for the better.
"What is important is that this non-invasive method has proven effective - it can be used as a basis to develop a clinical method," said one of the authors of the study Evgeniy Nikolaev, Professor at Moscow Institute of Physics and Technology.
From a doctor's point of view, one of the main symptoms of preeclampsia is a marked increase in the level of protein in the urine.
So the scientists wondered whether peptides (pieces of proteins) that are produced by women with preeclampsia could carry information about the disease.
To identify potential peptide biomarkers, the researchers compared samples of three groups of ten women -- with a normal pregnancy, and with mild and severe preeclampsia.
The researchers were not only interested in comparing healthy women and patients with preeclampsia, they also wanted to examine how certain biomarkers are associated with the severity of the condition.
Following the experiments, 35 potential peptide biomarkers of preeclampsia were identified.
A paper detailing the results was published in the Journal of Proteomics.
"We were able to confirm a number of markers previously proposed by our colleagues abroad, and also identify some new ones. We will obviously need to verify and confirm their significance," Nikolaev said.
--IANS
gb/vm
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
